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Prevalence of metabolic syndrome among Iranian Women with Polycystic Ovary 
Syndrome: A Systematic Review and Meta-analysis 
Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that is 
associated with an increased the risk of metabolic syndrome (MetS) and hence increased 
cardiovascular diseases in women. This systematic review and meta-analysis aimed at 
examining the prevalence of MetS in Iranian women with PCOS. 
Methods: This was a systematic review and meta-analysis of English and  Persian studies, 
using the following keywords: Polycystic Ovary Syndrome, Hyperandrogenism, Metabolic 
Syndrome,"MetSyn," X Syndrome, and Iran in sevarl national and international databases 
(Scientific Information Database (SID), Magiran, Web of Science, Google Scholar, PubMed, 
and Scopus from inception to February 2019. Heterogeneity among the studies was assessed 
using the Cochran's Q test. The random affects model was then used to estimate the overall 
prevalence of MetS. ALL the analyses were performed using STATA, version 12. 
Results: Overall, 10 studies were included in the study. The overall prevalence of MetS among 
Iranian women with PCOS was 26.6% (95% CI: 16.60-31.70). In addition, the mean body mass 
index (BMI) was 27.47 (95% CI: 25.46-29.48) and the mean waist circumference was 87.94 
(95% CI: 84.28-91.60). According the meta-regression results, there were no significant 
associations between the prevalence of MetS and sample size, year of publication, waist 
circumference, BMI, and age. 
Conclusion: One-fourth of Iranian women with PCOS have MetS. Given the overlap between 
anthropometric and metabolic abnormalities in PCOS and the features of MetS, accurate 
identification of patients with MetS is important to ensure early diagnosis and subsequent 
interventions to effectively manage the condition. Keywords: Polycystic ovary syndrome, 
Metabolic syndrome, Prevalence, Systematic review, Meta-analysis, Iran 
  
Introduction 
Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorders in women 
of reproductive age that is characterized by chronic non ovulation and hyperandrogenism (1). 
In addition to infertility, PCOS is accompanied by psychological problems (e.g. increased 
anxiety and depression, reduced quality of life) and metabolic disorders (impaired glucose 
tolerance (IGT), diabetes (2). Although the etiology of PCOS remains unknown, certain genetic 
and environmental factors make certain women vulnerable to this syndrome (3). Patients with 
PCOS are always at risk of  dyslipidemia, obesity, and hypertension and hence higher risk of 
cardiovascular diseases (4, 5). Insulin resistance and compensatory hyperinsulinemia are 
among the main factors involved in PCOS (6). One-third of patients with PCOS have IGT, and 
7.5% have diabetes (7). 
Wild et al. (2000) showed that women with PCOS were 2.2, 1.4, and 2.8 times more likely than 
those without this syndrome to have diabetes, hypertension, and cardiovascular disease, 
respectively (8). There is a considerable overlap between many of anthropometric and 
metabolic abnormalities in PCOS and the features of metabolic syndrome (MetS) that is a 
collection of cardiovascular risk factors including high blood pressure, central obesity, elevated 
fasting plasma glucose concentrations, and low levels of high-density lipoprotein (HDL) 
cholesterol (5)(9). It is predicted that this pandemic will affect half of the world’ population in 
the next 20 years (10). The risk of myocardial infarction and stroke is twice as high in patents 
with MetS as those without it (11). 
Previous studies focused on the prevalence of MetS in Iranian women with PCOS have 
reported different results, with  prevalence rates ranged from 7.1% to 46.4% (12, 13). Given 
the negative consequences of MetS (e.g. cardiovascular disease, diabetes) for those with PCOS, 
determining its overall prevalence in the Iranian population can help policymakers and 
healthcare providers design interventions aimed at effective and early prevention, control, and 
management of MetS in Iranian women with PCOS. 
Methods 
Search strategy 
In this study, the prevalence of MetS in Iranian women with PCOS was analyzed based on 
articles published in national and international journals without time limitation and based on 
the PRISMA statement (14). The search was conducted in national databases of Scientific 
Information Database (SID) and Magiran and international databases of Web of Science, 
Google Scholar, PubMed, and Scopus, using the following keywords: Polycystic Ovary 
Syndrome, Hyperandrogenism, Metabolic syndrome, "MetSyn," and X syndrome and their 
possible combinations. In the Iranian databases, the Persian equivalents of the keywords were 
utilized. The references of the articles were also examined to access more relevant articles. 
Study selection and data extraction 
All the studies in Persian or English, reporting the prevalence of MetS in Iranian women with 
PCOS were included in the analysis. The exclusion criteria were  review studies, interventional 
studies, letters to the editor, repeated studies, and full text not available. Two researchers 
independently reviewed the titles and abstracts, and extracted the full texts of relevant studies. 
Disagreements between the two researchers would be resolved by the correspondent author 
who was experienced in meta-analysis. The selected articles’ characteristics, including name 
of the first author, year of publication, city of study, methodical quality, total sample size, 
number of women with PCOS and MetS included in the study, and mean age, mean body mass 
index (BMI), and mean waist circumference of the samples, were recorded on a spreadsheet. 
Statistical analysis 
The variance was calculated using a binomial distribution, and the weighted mean was used to 
combine prevalence rates in different studies. Heterogeneity among the selected studies was 
assessed using the Cochran’s Q Test and the I2 statistic, and was classified into three categories: 
below 25% (low heterogeneity), 25-75% (moderate heterogeneity), and above 75% (high 
heterogeneity). Sensitivity analysis was used to examine the role of each study in the pooled 
prevalence. Subgroups analysis was used to examine the prevalence of MetS based on 
methodological quality and the diagnostic criteria of MetS, and a Funnel plot based on the 
Egger's test was used to examine publication bias. The univariate meta-regression analysis was 
utilized to assess the association between the prevalence of MetS in women with PCOS with 
year of study, sample size, and samples’ mean age, mean BMI, and mean waist circumference. 
All the analyses were performed using Stata, version 12. 
Results 
Characteristics of the included studies 
Among the 363 articles identified  from the national and international databases, a total of 347 
articles were excluded from the analysis. Among the 16 remaining articles, another 6 studies 
were excluded (4 articles were focused on a different target population, one article had not 
reported the prevalence of MetS, and one article had incomplete data. Finally, a total of 10 
articles were analyzed based on the PRISMA statement. 
 
Figure 1. Process of selecting and screening the studies based on the PRISMA statement. 
 
The total sample size was 1353 (135 participants per study on average). Sample size ranged 
from 30 to 282 patients. In terms of methodological quality, four articles had a good quality 
and seven articles had a moderate quality. In terms of diagnostic criteria for MetS, seven 
articles had used the ATP III, two articles had used the JIS, and one article had used the IDF. 
 
Table 1. Characteristics  of the selected articles. 
Preval
ence 







28.8 ATP III 28.98±11.19 Rasht 215 2016 Zahiri (15) 
19.7 ATP III 29.80±3.40 Tehran 123 2016 Madani (16) 
7.10 JIS - Khouzestan  85 2014 Ramezani Tehrani (12) 
39.50 ATP III 27.12±2.34 Tabriz 200 2013 
Pourteymourfard 
Tabrizi (17) 
15 ATP III 23.90±0.20 Qazvin 78 2013 Ziaee (18) 
33.3 DIF 23.40±3.09 Zanjan 30 2012 Rahmanpour (19) 
22.7 ATP III - Tehran 282 2012 Moeini (20) 
18.5 JIS 26.4±5.8 Tehran 136 2011 Hosseinpanah (21) 
13.5 ATP III 31.4±5.2 Ahvaz 53 2011 Shahbazian (22) 
46.4 ATP III 29±7 Tehran 151 2009 Moradi (13) 
  
Meta-analysis 
The overall prevalence of MetS in women with PCOS was 24.1% (95% CI: 16.60-31.70). In 
addition, the prevalence of MetS in women with PCOS based on the ATP III and the JIS criteria 
was 26.60% (95% CI: 18.37-34.83) and 12.65% (95% CI: 1.49-23.82), respectively. Moreover, 
the findings showed that the prevalence of MetS was higher in the articles with a higher 
methodological quality (29.98%; 95% CI: 20.74-39.22) than those with a moderate quality 
(20.45%; 95% CI: 10.40-30.51). 
 
Figure 2: Forest plot of the prevalence of MetS in women with PCOS. The 95% confidence interval for each 
study is shown in the form of horizontal lines around the central mean, the midpoint of the dotted line represents 
the mean overall score, and the lozenge shape shows the confidence interval of the prevalence rate. 
 
The mean age of the samples was 26.53 years. In addition, the mean BMI and mean waist 
circumference in the participants were 27.47 (95% CI: 25.46-29.48) and 87.94 (95% CI: 84.28-
91.60), respectively. The results of meta-regression analysis indicated no significant 
relationship between the prevalence of MetS in women with PCOS and year of publication 
(P=0.375), sample size (P=0.299), mean age (P=0.473), mean BMI (P=0.941), and mean waist 
circumference (P=0.451). 
 
Figure 3: Meta-regression of the prevalence of MetS in women with PCOS. The prevalence of MetS based on 
BMI (A), Waist circumference (B), Year of publication (C), and mean age of samples (D). Circles indicate the 
weight of the studies. 
 
According to the results of sensitivity analysis, the removal of each study did not lead to a 
significant change in the pooled prevalence of MetS. In addition, the publication error was not 
significant (P=0.521). 
 
Figure 4: Publication bias 
Discussion 
The aim of the present systematic review and meta-analysis was to examine the overall 
prevalence of MetS in Iranian women with PCOS. According to the results, the prevalence of 
MetS in Iranian women with PCOS was 24.15%, with large variation deepening on the MetS 
diagnostic tool used in the study In other words, about one-fourth of Iranian women with PCOS 
also suffer from MetS; this is consistent with the prevalence rate reported in Brazil (23). The 
high prevalence of MetS in patients with PCOS is not surprising, given that there are common 
features between PCOS and MetS, and that  both conditions are related to insulin resistance. In 
Asia, prevalence rates of 37.5% (India) and 35.3% (Thailand) have been reported for MetS in 
women with PCOS (24, 25). 
Two other studies have reported prevalence rates of 46% and 43% for MetS among American 
women with PCOS (6, 26). In a study conducted in Italy, the prevalence of MetS in women 
with PCOS based on the ATP III and WHO criteria was found to be 8.2% and 16%, respectively 
(27). Different prevalence rates in the studies could be  due to different genetic factors, dietary 
habits, physical activity levels, and lifestyles. On reason for the variations in  prevalence of 
MetS in Iranian women is that there are multiple definitions for this syndrome. For example, 
given the small physique of the Asian population compared to the Europeans, some studies in 
Asia have used a modified criteria to diagnose MetS, according to which a waist circumference 
greater than 80 cm is a common feature of those with MetS (9, 28). The studies analyzed in the 
present meta-analysis had not used modified criteria of MetS; this can partly explain the 
relatively lower prevalence of MetS among Iranian women with PCOS. 
A meta-analysis by Fazleen et al. showed that women with PCOS were 2.7 times more likely 
than those without PCOS to develop MetS (3). Contrary to the results of the aforementioned 
studies, Vibrikova et al. found no significant difference between women with PCOS and 
healthy women in the prevalence of PCOS (29). In a study by Glueck et al. among 138 women 
with PCOS, a prevalence rate of 46% was found for MetS (26). Apridonidze et al. also reported 
a prevalence of 43% for MetS in women with PCOS (6). 
In the present study, no significant relationship was found between prevalence of MetS and 
age, BMI, waist circumference, and year of publication. A study by Soares showed that the 
prevalence of MetS increased with BMI, so that it was 3.2%, 19.2%, and 52.3% in normal, 
overweight, and obese women, respectively (23). In addition, insulin resistance is intensified 
in the presence of obesity; more than 40% of patients with PCOS suffer from obesity (30). 
Lergo also believes that 70% of these women have impaired lipid levels (31). A study in Italy 
showed that the prevalence of MetS in women with PCOS increased with age, so that it was 
12.1% in women aged 20-24 years, 31.7% in women aged 25-29 years, and 42.9% in women 
aged 30-34 years (27). 
One of the strengths of the present study was that it was the first meta-analysis in Iran focused 
on examining and reporting the overall prevalence of MetS in women with PCOS. The study 
results can be useful in making health decisions and also in conducting future studies on this 
issue. On the other hand, some of the necessary information were missing in a number of the 
analyzed studies; this can be regarded as a limitation of the present study.. Given the increased 
risk of morbidity associated with MetS, it seems necessary to identify those women with PCOS 
who are at risk of developing MetS, and provide them with effective interventions aimed at 
controlling and treating their symptoms. 
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